Founder and Chairman of the Scientific Advisory Board
Professor Fabio Prati has been interested in the chemistry of boronic acids since the late ’90s. Under his guidance, his team has synthesised several boronic acids for different applications, ranging from asymmetric synthesis of biologically-active compounds or chiral derivatising agents to enzyme inhibitors. In this respect, his group has successfully obtained the most potent inhibitor ever described of the class C beta-lactamase. He is currently part of two international research projects funded by the National Institute of Health (Principal Investigator Professor R.A. Bonomo and Professor B.K. Shoichet). Professor Prati is author of more than 75 publications and two patents.
Founder and Director of Research
Dr Emilia Caselli obtained her Bachelor of Science in Pure and Applied Chemistry at Strathclyde University (Glasgow) and graduated in chemistry at the University of Modena and Reggio Emilia, where she also obtained her PhD in Chemical Sciences. During her PhD she spent 18 months in Professor B.K. Shoichet’s laboratory at Northwestern University (Chicago), working on the kinetics and modeling of beta-lactamase inhibitors. Thereafter she joined Professor Prati’s laboratory, where she spent more than 10 years in asymmetric synthesis of boronic acids. By means of proprietary synthetic methodologies she has obtained novel BLIs active on clinically relevant -lactamases and is actively involved in research collaborations with international groups active in the field. She is author of 25 publications and co-inventor of two patents.
Dr. Tino Rossi has more than 30 years experience in Drug Discovery and Development both in the
Pharmaceutical industry and in Contract Research Organizations where he has developed extensive
experience in Medicinal Chemistry, Chemical Development, Drug Metabolism & Pharmacokinetics
and Preclinical Development in a wide range of Drug Discovery phases from Target identification
to Phase II clinical trials in multiple indications, including Antibacterial, Central Nervous System and
Metabolic & Cardiovascular disorders.
Dr. Tino Rossi has directly contributed to the identification and progression into the development
phases of 45 New Chemical Entities. He is co-inventor of 9 patents and author of 43 publications in
quality, peer-reviewed journals.
Founder and Business Development
Dr Nicholas Draeger has 20 years of professional healthcare experience in fields including pharmaceutical research, health economics research at the University Hospital Basel, with 22 publications and 1 patent to his name, international business development, M&A (Roche and Recordati) and investments relating to medical devices, pharmaceuticals and biotech from both an industry and investment banking perspective (Credit Agricole and Adamant). He has provided business development and M&A services, and investment advisory services in the medical technology and biotech sectors for numerous companies and healthcare funds, and the government of South Africa. He has co-founded several healthcare companies and a nutritional company.